{"filing":{"accession_number":"0001193125-26-342397","cik":"0001850270","ticker":"PROK","company_name":"PROKIDNEY CORP.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"prok-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/prok-20260810.htm"},"events":[{"id":26580,"run_id":24162,"accession_number":"0001193125-26-342397","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ProKidney issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, with consolidated balance sheets, statements of operations, and cash flow statements attached as Exhibit 99.1. The disclosure includes Q2 2026 financial highlights (cash position of $181.6 million, R\u0026D expenses of $36.1 million, net loss of $46.4 million) and material business milestones (completion of accelerated approval efficacy analysis enrollment, appointment of Chief Technical Officer). This is a standard quarterly earnings release disclosure under Item 2.02.","company_name":"PROKIDNEY CORP.","ticker":"PROK","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27750,"accession_number":"0001193125-26-342397","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ProKidney issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, with consolidated balance sheets, statements of operations, and cash flow statements attached as Exhibit 99.1. The disclosure includes Q2 2026 financial highlights (cash position of $181.6 million, R\u0026D expenses of $36.1 million, net loss of $46.4 million) and material business milestones (completion of accelerated approval efficacy analysis enrollment, appointment of Chief Technical Officer). This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:19:50.890568+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27750,"accession_number":"0001193125-26-342397","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ProKidney issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, with consolidated balance sheets, statements of operations, and cash flow statements attached as Exhibit 99.1. The disclosure includes Q2 2026 financial highlights (cash position of $181.6 million, R\u0026D expenses of $36.1 million, net loss of $46.4 million) and material business milestones (completion of accelerated approval efficacy analysis enrollment, appointment of Chief Technical Officer). This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:19:50.890568+00:00","company_name":"PROKIDNEY CORP.","ticker":"PROK","filing_date":"2026-08-10"}]}